Journal

Medicare GLP-1 Bridge: $50 a Month, and What the Fine Print Says

A temporary federal programme now covers GLP-1s for weight loss at a flat $50 copay — the first time Medicare has done so.

Why this is unusual

Federal law excludes drugs used for weight loss from Medicare Part D coverage. That exclusion is the reason millions of older adults have been paying cash for medications their commercially insured neighbours get for a copay.

The GLP-1 Bridge sidesteps it. Run by the Centers for Medicare & Medicaid Services as a demonstration programme rather than as ordinary Part D coverage, it provides eligible beneficiaries certain GLP-1 medications at a flat $50 monthly copayment. A central Medicare system handles approvals, claims and pharmacy payment; your Part D plan does not have to participate and is not the route.

What it covers

Four products: Wegovy (injectable semaglutide), Zepbound (tirzepatide), the Wegovy pill (oral semaglutide 25 mg) and Foundayo (orforglipron). All four at the same $50, which produces an interesting consequence — the copay flattens the price differences between products that range from $149 to $449 on self-pay.

If you qualify, the question stops being which is cheapest and becomes which is most effective and best tolerated for you. On mean weight reduction, tirzepatide leads at about 20.9% in SURMOUNT-1, oral semaglutide reported 13.6% to 16.6% in OASIS 4, and orforglipron approximately 11% to 12.4% in ATTAIN-1.

The timeline, and why it matters

The programme began 1 July 2026. CMS originally indicated it would run to the end of 2026, with a successor — the BALANCE Model, intended to lower prices through direct negotiation — starting in January 2027.

In May 2026 CMS announced that the Part D portion of BALANCE has been delayed indefinitely, and extended the Bridge through 31 December 2027 instead.

So the practical position: eighteen months of access, with no confirmed programme behind it. That is worth planning around rather than assuming continuity. If you start treatment under the Bridge, the question of what happens on 1 January 2028 is a real one, and the withdrawal evidence says stopping is followed by substantial regain.

What this does to the compounded market

For anyone eligible, it largely ends the argument. A $50 copay on an FDA-approved product with published trial data, manufacturer supply and a known safety profile is below every compounded programme in our dataset — the cheapest of which is $110 a month for a microdose that sits below any studied dose.

It also arrives as the FDA proposes closing the last pathway for large-scale compounding of these molecules, with the comment period on that proposal closing 30 July 2026. The two developments together suggest a market reorganising around approved products rather than around compounded alternatives.

For anyone not eligible — most people under 65 without commercial coverage — nothing changes. Self-pay remains the market, and the comparison worth running is manufacturer-direct against compounded, where flat-rate compounded programmes from $186 a month compete against $299 to $449 for brand Zepbound direct from LillyDirect.

What to establish if you think you qualify

1. Confirm eligibility with Medicare directly, not with a telehealth platform. This is a CMS demonstration and the central system handles approvals.
2. Ask which of the four products your prescriber recommends and why. At an identical copay, the choice is clinical rather than financial for the first time in this category.
3. Ask what happens after December 2027. Nobody knows yet, and a clinician who says so plainly is being straight with you.
4. If you currently pay cash for a compounded product, price the Bridge first. $50 against $110 to $399 is not a close comparison.

What this does not do

It does not make GLP-1s a standard Part D benefit — the statutory exclusion is untouched. It does not cover everyone on Medicare; eligibility criteria apply. It is not permanent. And it does not remove the clinical questions: the contraindications, the boxed warning for thyroid C-cell tumours, and the evidence that treatment appears to require continuation all apply regardless of who is paying.

Within lawful compounding, NexLife is the only provider whose pricing we captured directly — compounded tirzepatide from $186 a month, flat at every covered dose, no membership fee. See its plans.

Questions readers actually ask